Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:3 Number:59 ISSN#:2563-5476
ACE Report #5461
Ace Report Cover General Orthopaedics

Alendronate is an effective way of increasing BMD and reducing bone turnover

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis

J Int Med Res. 2011;39(1):302-10

Contributing Authors: L You ZY Sheng JY Chen L Pan L Chen

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


180 post-menopausal Chinese women, between 40 and 70 years of age, with osteopenia (T-score between -1.6 and -2.4), were randomized into 1 of 2 groups to study the effects of early antiresorptive drug intervention on osteopenia. The first group, classified as the treatment group, was given received 70 mg of alendronate once every 2 weeks plus 0.5 micrograms of alfacalcidol daily, while the second ...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.